Compare ASTRAZENECA PHARMA with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ALEMBIC LTD - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ALEMBIC LTD ASTRAZENECA PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 73.0 70.5 103.5% View Chart
P/BV x 20.6 2.5 820.7% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ASTRAZENECA PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
ALEMBIC LTD
Mar-18
ASTRAZENECA PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs1,27872 1,775.0%   
Low Rs88334 2,603.5%   
Sales per share (Unadj.) Rs228.44.7 4,859.0%  
Earnings per share (Unadj.) Rs10.46.1 169.8%  
Cash flow per share (Unadj.) Rs16.36.2 260.4%  
Dividends per share (Unadj.) Rs00.20 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs98.840.7 242.9%  
Shares outstanding (eoy) m25.00267.03 9.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.711.3 42.0%   
Avg P/E ratio x104.28.7 1,201.5%  
P/CF ratio (eoy) x66.48.5 783.6%  
Price / Book Value ratio x10.91.3 839.9%  
Dividend payout %03.3 0.0%   
Avg Mkt Cap Rs m27,00814,139 191.0%   
No. of employees `0001.4NA-   
Total wages/salary Rs m1,535207 740.3%   
Avg. sales/employee Rs Th4,210.9NM-  
Avg. wages/employee Rs Th1,132.2NM-  
Avg. net profit/employee Rs Th191.1NM-  
INCOME DATA
Net Sales Rs m5,7101,255 454.9%  
Other income Rs m123370 33.1%   
Total revenues Rs m5,8331,625 358.8%   
Gross profit Rs m463111 416.7%  
Depreciation Rs m14738 389.9%   
Interest Rs m02 0.0%   
Profit before tax Rs m438442 99.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m17924 747.0%   
Profit after tax Rs m2591,630 15.9%  
Gross profit margin %8.18.9 91.6%  
Effective tax rate %40.85.4 753.5%   
Net profit margin %4.5129.8 3.5%  
BALANCE SHEET DATA
Current assets Rs m3,2091,867 171.9%   
Current liabilities Rs m2,070591 350.1%   
Net working cap to sales %20.0101.6 19.6%  
Current ratio x1.63.2 49.1%  
Inventory Days Days7294 76.7%  
Debtors Days Days3574 47.5%  
Net fixed assets Rs m7901,791 44.1%   
Share capital Rs m50534 9.4%   
"Free" reserves Rs m2,41910,324 23.4%   
Net worth Rs m2,46910,858 22.7%   
Long term debt Rs m041 0.0%   
Total assets Rs m4,60511,591 39.7%  
Interest coverage xNM260.9-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.1 1,144.9%   
Return on assets %5.614.1 40.0%  
Return on equity %10.515.0 69.9%  
Return on capital %17.715.2 116.8%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m30019 1,544.1%   
Fx outflow Rs m2,015264 763.7%   
Net fx Rs m-1,715-244 701.8%   
CASH FLOW
From Operations Rs m88236 37.3%  
From Investments Rs m-94-224 41.8%  
From Financial Activity Rs mNA-27 0.0%  
Net Cashflow Rs m-6-15 38.5%  

Share Holding

Indian Promoters % 0.0 64.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.2 150.0%  
FIIs % 15.7 9.7 161.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 26.1 34.9%  
Shareholders   12,856 54,701 23.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   CIPLA  PFIZER  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Metal and Banking Stocks Drag(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1% while the Hang Seng is up 1.1%.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 19, 2019 11:35 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS